Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa

Abstract

We evaluated whether droxidopa, a prodrug converted to norepinephrine, is beneficial in the treatment of symptomatic neurogenic orthostatic hypotension, which results from failure to generate an appropriate norepinephrine response to postural challenge. Patients with symptomatic neurogenic orthostatic hypotension and Parkinson disease, multiple system atrophy, pure autonomic failure, or nondiabetic autonomic neuropathy underwent open-label droxidopa titration (100-600 mg, 3× daily). Responders then received an additional 7-day open-label treatment at their individualized dose. Patients were subsequently randomized to continue with droxidopa or withdraw to placebo for 14 days. We then assessed patient-reported scores on the Orthostatic Hypotension Questionnaire and blood pressure measurements. Mean worsening of Orthostatic Hypotension Questionnaire dizziness/lightheadedness score from randomization to end of study (the primary outcome; N=101) was 1.9±3.2 with placebo and 1.3±2.8 units with droxidopa (P=0.509). Four of the other 5 Orthostatic Hypotension Questionnaire symptom scores and all 4 symptom-impact scores favored droxidopa, with statistical significance for the patient's self-reported ability to perform activities requiring standing a short time (P=0.033) and standing a long time (P=0.028). Furthermore, a post hoc analysis of a predefined composite score of all symptoms (Orthostatic Hypotension Questionnaire composite) demonstrated a significant benefit for droxidopa (P=0.013). There was no significant difference between groups for standing systolic blood pressure (P=0.680). Droxidopa was well tolerated. In summary, this randomized withdrawal droxidopa study failed to meet its primary efficacy end point. Additional clinical trials are needed to confirm that droxidopa is beneficial in symptomatic neurogenic orthostatic hypotension, as suggested by the positive secondary outcomes of this trial.

Clinical trial registration url: http://www.clinicaltrials.gov. Unique identifier: NCT00633880.

Keywords: Parkinson disease; autonomic nervous system; droxidopa; multiple system atrophy; norepinephrine.

© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wolters Kluwer.

Figures

Figure 1.

Study design (see text for details). Open arrows indicate that an orthostatic standing test (OST) was performed; filled arrows indicate that Orthostatic Hypotension Questionnaire (OHQ) and OST were performed. DB indicates double blind; and OL, open label.

Figure 2.

Subjects’ disposition flow diagram. *Post hoc analysis. BP indicates blood pressure; DB, double blind; and OL, open label.

Figure 3.

Mean (SE) values at baseline, during droxidopa administration, and after withdrawal for (A) dizziness/lightheadedness score (item 1 of the Orthostatic Hypotension Symptom Assessment Questionnaire, n=101) and (B) standing systolic blood pressure (SBP, n=100). Dashed lines denotes mean baseline values for reference; in a withdrawal design, the placebo group is expected to return to baseline.

Figure 4.

Treatment-group differences in Orthostatic Hypotension Questionnaire (OHQ) score changes from randomization to end of study (mean and 95% confidence intervals of all treated patients; last observation carried forward). *Average of items not scored zero at baseline; †P<0.05, droxidopa vs placebo, Wilcoxon rank-sum test; ‡Average of symptom and symptom-impact composite scores (post hoc analysis, missing data excluded). OHDAS indicates Orthostatic Hypotension Daily Activity Scale; and OHSA, Orthostatic Hypotension Symptom Assessment.